Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709576 · ClinicalTrials.gov registry record · Phase 2
Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03709576 is a Phase 2 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT03709576, a Phase 2 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This research is being done to find out the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML and to see the overall diseases free survival, relapse, and GVHD after treatment.
Interventions
- DRUG Azacitidine
- DRUG Pevonedistat
- PROCEDURE transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2019-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03709576
The ClinicalTrials.gov registry entry for NCT03709576 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT03709576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03709576 about?
NCT03709576 is a clinical study titled "Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML". This research is being done to find out the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML and to see the overall diseases free survival, relapse, and GVHD after treatment.
What is the current status of trial NCT03709576?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2018-07-18. Estimated completion is 2019-07-22.
What interventions are being tested in trial NCT03709576?
The interventions under investigation include: Azacitidine (DRUG), Pevonedistat (DRUG), transplant (PROCEDURE).
Who is sponsoring clinical trial NCT03709576?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.